Lexicon Pharmaceuticals, Inc. LXRX
Nov 4, 2026, 11:52 AM EST
- YTD
- +29.13%
- 1 year
- +11.65%
- Market cap
- 660.76M
- Revenue (ttm)
- 41.47M
- Profit margin
- -147.38%
- EPS (ttm)
- -0.16
- Shares out
- 444.96M
- Forward P/E
- -11.86
- YTD return
- +29.13%
- 1-year return
- +11.65%
- Volume
- 443.25K
- Avg volume
- 2.67M
- Open
- 1.50
- Previous close
- 1.46
- Day's range
- 1.46 – 1.54
- 52-week range
- 1.14 – 2.64
- Beta
- 1.03
- Analysts
- Buy
- Price target
- 3.86 (+159.7%)
- Earnings date
- Nov 5, 2026
5m 0.00 (0.00%)
Key statistics
- Enterprise value
- 865.33M
- PEG ratio
- -13.77
- Price / sales
- 24.25
- Price / book
- 5.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -97.60%
- Free cash flow
- -44.77M
- Total cash
- 190.61M
- Total debt
- 59.24M
- Return on equity
- -40.21%
- Short % of float
- 13.87%
- 50-day average
- 2.33
- 200-day average
- 1.78
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 3.86
- Target (high)
- 6.00
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.0529.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.06 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.05023 | -0.06 | -0.01 | -19.45% |
| May 7, 2026 | Mar 31, 2026 | -0.04 | -0.0026 | +0.04 | +93.50% |
| Mar 5, 2026 | Dec 31, 2025 | -0.07 | -0.04 | +0.03 | +42.86% |
| Nov 6, 2025 | Sep 30, 2025 | -0.07 | -0.04 | +0.03 | +42.86% |
| Aug 6, 2025 | Jun 30, 2025 | -0.08 | 0.01 | +0.09 | +112.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 11, 2026 | Citigroup | main | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 10, 2026 | Citigroup | main | Buy | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 2, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2025 | Citigroup | main | Buy | Buy |
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lexpharma.com
News
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 
Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design 
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy 
Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways 
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease 
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened 
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript 
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More 
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today 
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages
Your note
Sign in to keep a note on LXRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMOUYAL PHILIPPE | Director | Conversion of Exercise of derivative security | Jun 2, 2026 | 374,486 |
| ARTAL PARTICIPATIONS S.A.R.L. | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 29, 2026 | 0 |
| CRUM BRIAN T | General Counsel | Conversion of Exercise of derivative security | Feb 26, 2026 | 428,802 |
| DEBBANE RAYMOND | Director | Conversion of Exercise of derivative security | Jun 2, 2026 | 51,750,200 |
| EXTON MICHAEL | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 26, 2026 | 298,432 |
| GRANOWITZ CRAIG B. M.D., PH.D. | Officer | Conversion of Exercise of derivative security | Feb 26, 2026 | 323,430 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artal Group S.A. | 39.36% | 175,156,062 | 395.85M | Jun 29, 2026 |
| FMR, LLC | 11.64% | 51,782,045 | 117.03M | Jun 29, 2026 |
| Siren, L.L.C. | 9.96% | 44,303,518 | 100.13M | Jun 29, 2026 |
| Sessa Capital IM, L.P. | 4.26% | 18,960,836 | 42.85M | Jun 29, 2026 |
| Blackrock Inc. | 3.90% | 17,348,741 | 39.21M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.23% | 9,901,208 | 22.38M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.88% | 17,247,637 | 38.98M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.54% | 6,847,451 | 15.48M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.40% | 6,209,944 | 14.03M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.14% | 5,083,069 | 11.49M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.93% | 4,127,293 | 9.33M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.61% | 2,701,371 | 6.11M | Jun 29, 2026 |